Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

January 31, 2004

Conditions
Dyslipidemia/Glucose Metabolism Disorder
Interventions
DRUG

fenofibrate and metformin combination (drug)

Trial Locations (51)

Unknown

Site 201, Katowice

Site 203, Katowice

Site 202, Warsaw

Site 204, Zabrze

Site 111, Dnipropetrovsk

Site 113, Dnipropetrovsk

Site 108, Kharkiv

Site 109, Kharkiv

Site 101, Kyiv

Site 102, Kyiv

Site 103, Kyiv

Site 104, Kyiv

Site 105, Kyiv

Site 106, Kyiv

Site 107, Kyiv

Site 112, Zaporizhya

Site 35, Acomb

Site 21, Atherstone

Site 14, Balsall Common

Site 32, Bangor

Site 23, Barry

Site 36, Basingstoke

Site 8, Bexhill-on-Sea

Site 20, Camberley

Site 22, Chesterfield

Site 10, Chippenham

Site 13, Coventry

Site 31, Doncaster

Site 15, Downpatrick

Site 17, Ely

Site 4, Ely

Site 11, Fife

Site 1, Frome

Site 16, Harrow

Site 5, Hastings

Site 26, Haverfordwest

Site 19, Keresley End

Site 9, Kingswood

Site 25, Newtownabbey

Site 33, Northampton

Site 28, Odiham

Site 3, Paignton

Site 12, Peterborough

Site 7, Randalstown

Site 27, Slough

Site 6, Soham

Site 2, South Glamorgan

Site 34, Stratford-upon-Avon

Site 29, Swindon

Site 30, Trowbridge

Site 18, Yaxley

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00349128 - Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes | Biotech Hunter | Biotech Hunter